Hospital General Universitario Gregorio Marañón, Allergy Section, Madrid, Spain; Biomedical Research Network on Rare Diseases (CIBERER, U761), Madrid, Spain; Institute for Health Research Gregorio Marañón, Madrid, Spain.
Hospital Universitario Virgen del Rocío, Allergy Section, Sevilla, Spain; Instituto de Biomedicina de Sevilla, Sevilla, Spain.
J Allergy Clin Immunol Pract. 2022 Apr;10(4):1020-1028. doi: 10.1016/j.jaip.2021.11.018. Epub 2021 Nov 26.
Data on acquired angioedema due to C1-inhibitor deficiency (C1-INH-AAE) from 4 European countries (France, Italy, Germany, and Hungary) were recently published.
To report data from a group of 50 patients with acquired C1-INH deficiency from Spain, of whom 46 had angioedema, and compare them with other European series.
We performed a retrospective observational study of 46 patients with C1-INH-AAE and 4 asymptomatic patients. Clinical and biological characteristics and associated diseases were assessed and compared with other European series.
Women accounted for 73.9% of cases. The prevalence of C1-INH-AAE related to hereditary forms was 1/10.1. Overall, 8.7% patients were aged <40 years. Diagnostic delay was 1.1 years. Angioedema mainly affected the face (91.3%), followed by the oropharynx (63%), extremities (50%), and abdomen (37%). Only 1 patient underwent orotracheal intubation. Erythema marginatum was present in 1 patient. A hematologic disorder was recorded in 50% of patients. Angioedema preceded all benign conditions, mostly monoclonal gammopathy of undetermined significance, but appeared very close to or after malignant hematologic diseases (median, 2.2 and 0.29 years). Autoimmune diseases were associated in 50% (autoimmune thyroiditis, 21.5%; systemic lupus erythematosus, 10.9%). Half of them coexisted with hematologic disorders. Anti-C1-INH antibodies were found in 67% of tested patients and were not related to the associated disease. Long-term prophylaxis was necessary in 52.2%, most of whom responded to tranexamic acid.
This study emphasizes the possibility of C1-INH-AAE in patients younger than 40 and in autoimmune diseases other than systemic lupus erythematosus such as autoimmune thyroiditis.
最近发表了来自法国、意大利、德国和匈牙利等 4 个欧洲国家的关于 C1 抑制剂缺乏症(C1-INH-AAE)所致获得性血管性水肿的数据。
报告来自西班牙的一组 50 例获得性 C1-INH 缺乏症患者的数据,其中 46 例有血管性水肿,并与其他欧洲系列进行比较。
我们对 46 例 C1-INH-AAE 患者和 4 例无症状患者进行了回顾性观察性研究。评估了临床和生物学特征以及相关疾病,并与其他欧洲系列进行了比较。
女性占病例的 73.9%。与遗传性形式相关的 C1-INH-AAE 的患病率为 1/10.1。总体而言,8.7%的患者年龄<40 岁。诊断延迟为 1.1 年。血管性水肿主要累及面部(91.3%),其次是口咽部(63%)、四肢(50%)和腹部(37%)。仅有 1 例患者接受了经口气管插管。1 例患者存在红斑边缘。50%的患者存在血液学异常。血管性水肿先于所有良性疾病出现,主要为意义未明的单克隆丙种球蛋白血症,但与恶性血液病非常接近或紧随其后(中位数分别为 2.2 年和 0.29 年)。50%的患者伴有自身免疫性疾病(自身免疫性甲状腺炎,21.5%;系统性红斑狼疮,10.9%)。其中一半患者同时伴有血液学异常。在接受检测的患者中,67%发现了抗 C1-INH 抗体,但与相关疾病无关。52.2%的患者需要长期预防治疗,其中大多数对氨甲环酸有反应。
本研究强调了 C1-INH-AAE 可能发生在年龄<40 岁的患者和自身免疫性疾病(如系统性红斑狼疮以外的自身免疫性甲状腺炎)患者中。